Status: Not yet recruiting
A Dose Regimen Study of BRM421 Ophthalmic Solution in Patients With Dry Eye Disease
To evaluate the safety and efficacy of BRM421 Ophthalmic Solution compared to artificial tear for treatment of the signs and symptoms of dry eye disease (DED)
Participants needed: 99
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: BRIM Biotechnology Inc.Updated: Oct 20, 2025Locations: 1
Eligibility criteria
Are ≥18 years of age; [+3]
Within 3 months prior to Visit 1, have participated in any other investigational... [+3]